Hester Biosciences Ltd.

NSE: HESTERBIO | BSE: 524669 | ISIN: INE782E01017 | Industry: Pharmaceuticals
| Expensive Performer
2340.05 -7.50 (-0.32%)
NSE Jan 24, 2022 15:31 PM
Volume: 8,181

Hester Biosciences Ltd.    
28 Oct 2021

Hester Biosciences Limited Q2 and H1 FY22 Financial Highlights:

  • Revenue up by 6% and 24%, for Q2 and H1 FY22
  • Net Profit up by 16% and 35%, for Q2 and H1 FY22
  • Sales for Q2 FY22 and Q1 FY22 grew by 6% and 50% with overall H1 FY22 being higher by 24% as compared to corresponding periods. 
  • Overall, the sales of vaccines have registered a growth of 13% in Q2 FY22 and 26% in H1 FY22, and the sales of Health Products have registered a growth of 31% in Q2 FY22 and 53% in H1 FY22. 
  • Domestic sales have registered a growth of 21% in Q2 FY22 and 38% in H1FY22. There is marginal decrease in export sales in Q2 and H1 FY22. Export orders are affected due to restricted cargo movements globally. 




Result PDF

Hester Biosciences Ltd. is trading below all available SMAs